ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value

Oncogene

Volumn 22, Issue 3, 2003, Pages 456-460

  Vandesompele, Jo ^a   Edsjö, Anders ^b   De Preter, Katleen ^a   Axelson, Håkan ^b   Speleman, Frank ^a   Påhlman, Sven ^b,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LUND UNIVERSITY   (Sweden)

^c MAS   (Sweden)

Author keywords

ID2; MYC; MYCN; Neuroblastoma; Prognosis

Indexed keywords

GENE PRODUCT; INHIBITOR OF DIFFERENTIATION 2; PROTEIN MYCN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NEUROBLAST; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR CELL;

COHORT STUDIES; DNA-BINDING PROTEINS; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; NERVOUS SYSTEM NEOPLASMS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0037461898     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206148     Document Type: Article

References (20)

1. Bown N. (2001). J. Clin. Pathol., 54, 897-910.
2. Breit S and Schwab M. (1989). J. Neurosci. Res., 24, 21-28.
3. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, Francotte N, Board J, Pearson AD, De Paepe A, Van Roy N and Vandesompele J. (2002). Mod. Pathol., 15, 159-166.
4. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L and Påhlman S. (1996). Lab. Invest., 75, 659-675.
5. Hoehner JC, Hedborg F, Eriksson L, Sandstedt B, Grimelius L, Olsen L and Påhlman S. (1998). Lab. Invest., 78, 29-45.
6. Judware R and Culp LA. (1995). Oncogene, 11, 2599-2607.
7. Jögi A, Persson P, Grynfeld A, Påhlman S and Axelson H. (2002a) J. Biol. Chem., 277, 9118-9126.
8. Jögi A, Øra I, Nilsson H, Lindeheim Å, Makino Y, Poellinger L, Axelson H and Påhlman S. (2002b). Proc. Natl. Acad. Sci. USA, 99, 7021-7026.
9. Lasorella A, Noseda M, Beyna M, Yokota Y and Iavarone A. (2000). Nature, 407, 592-598.
10. Lasorella A, Uo T and Iavarone A. (2001). Oncogene, 20, 8326-8333.
11. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A and Iavarone A. (2002). Cancer Res., 62, 301-306.
12. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A and Schwab M. (1996). Oncogene, 13, 803-812.
13. Maris JM and Matthay KK. (1999). J. Clin. Oncol., 17, 2264-2279.
14. Reiter JL and Brodeur GM. (1998). Genes Chromosomes Cancer, 23, 134-140.
15. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K and Kondoh H. (1993). Development, 117, 1445-1455.
16. Vandesompele J, De Paepe A and Speleman F. (2002a). Anal. Biochem., 303, 95-98.
17. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe and Speleman F. (2002b). Genome Biol., 3, research 0034.1-0034.11.
18. Wakamatsu Y, Watanabe Y, Nakamura H and Kondoh H. (1997). Development, 124, 1953-1962.
19. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM. (1997). EMBO J., 16, 2985-2995.
20. Zebedee Z and Hara E. (2001). Oncogene, 20, 8317-8325.